OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) and Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Risk and Volatility
OnKure Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for OnKure Therapeutics and Anebulo Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OnKure Therapeutics | 0 | 0 | 4 | 2 | 3.33 |
| Anebulo Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Insider and Institutional Ownership
91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares OnKure Therapeutics and Anebulo Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OnKure Therapeutics | N/A | -51.17% | -47.11% |
| Anebulo Pharmaceuticals | N/A | -119.54% | -108.08% |
Earnings and Valuation
This table compares OnKure Therapeutics and Anebulo Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OnKure Therapeutics | N/A | N/A | -$77.39 million | ($6.57) | -0.29 |
| Anebulo Pharmaceuticals | N/A | N/A | -$8.20 million | ($0.28) | -3.71 |
Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
OnKure Therapeutics beats Anebulo Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About OnKure Therapeutics
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
